Approaches to Pharmaceutical Analysis of an Innovative Liposomal Preparation for Treating Hepatitis C


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The composite Y14/siUTR, a complex consisting of cationic lipopeptide Y14 as an excipient and pharmaceutical substance of small interfering RNAtargeted against the UTR region of hepatitis C virus (siUTR), was investigated. The composite was intended to inhibit the hepatitis C virus replication cycle. The present work was aimed at developing pharmaceutical analytical methods for the components of this composite using HPLC-UV and UV spectroscopy.

作者简介

V. Smirnov

Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation; Institute of Immunology, Federal Medico-Biological Agency of the Russian Federation; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: chem@folium.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051; Moscow, 115478; Moscow, 119991

L. Krasnykh

Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation

Email: chem@folium.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051

I. Shilovskii

Institute of Immunology, Federal Medico-Biological Agency of the Russian Federation

Email: chem@folium.ru
俄罗斯联邦, Moscow, 115478

A. Ryzhenkova

I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: chem@folium.ru
俄罗斯联邦, Moscow, 119991

M. Khaitov

Institute of Immunology, Federal Medico-Biological Agency of the Russian Federation

Email: chem@folium.ru
俄罗斯联邦, Moscow, 115478

V. Drozdov

I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: chem@folium.ru
俄罗斯联邦, Moscow, 119991


版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2018
##common.cookie##